Area:
Cognitive neuroscience; schizophrenia
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Scot Kristian Hill is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2006 — 2010 |
Hill, Scot Kristian |
K23Activity Code Description: To provide support for the career development of investigators who have made a commitment of focus their research endeavors on patient-oriented research. This mechanism provides support for a 3 year minimum up to 5 year period of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators. |
Enhancing Cognition in Schizophrenia @ Rosalind Franklin Univ of Medicine &Sci
DESCRIPTION (provided by applicant): Cognitive deficits are a persistent and debilitating aspect of schizophrenia. Developing pharmacological treatments to reduce these deficits is becoming a primary focus of drug development and clinical trials. The clinical neuropsychological tests most widely used to test for cognitive enhancement efficacy were not designed to track cognitive change over time or be sensitive to behavioral effects of drugs targeting specific neurotransmitter systems. The field needs clinical investigators with the skills to 1) develop and evaluate new tools, with potential for increased sensitivity and efficiency in monitoring cognitive change, which are based on contemporary cognitive neuroscience and animal models of behavioral pharmacology, and 2) apply these tools in fMRI studies to directly assess drug effects on brain systems and provide a more efficient evaluation of drug effects in this population. This line of work offers excellent promise for facilitating the emergence of effective new pharmacological treatments targeting cognitive deficits in schizophrenia. The primary objectives of the proposed career development activities are to enhance the candidate's expertise in the areas of animal models of working memory, cognitive neuroscience, behavioral pharmacology, and functional brain imaging. This will prepare the candidate to lead an independent program of research evaluating cognitive enhancement medications for schizophrenia. Research activities will focus on conducting the behavioral and functional imaging studies to characterize serial order processing paradigms from cognitive neuroscience. This foundation of empirical data is needed to justify research strategies and neurocognitive tools prior to moving forward in evaluating treatment effects on cognition in clinical trial settings.
|
0.979 |